Zastrzeżyńska W, Przybyszowski M, Bazan-Socha S, et al. - In this study with 13 patients treated with omalizumab for severe allergic asthma, researchers assessed airway structural alterations during the omalizumab therapy. Prior to and following the therapy, clinical, laboratory, and spirometry parameters were assessed in each patient. Findings revealed a reduction in the basal lamina thickness, fibronectin, but not collagen deposits in the bronchial mucosa as a result of omalizumab therapy. Improved asthma control and quality of life, as well as a diminished dose of systemic corticosteroids were observed in relation to reduction in fibronectin accumulation. Overall, findings revealed that unfavorable structural airway alterations in allergic asthmatics may be reduced, at least with respect to the fibronectin deposit and an increased thickness of the basal lamina, with omalizumab therapy, which is effective in the treatment of severe allergic asthma.